Torben Laursen

Overnight versus 24 hours of continuous subcutaneous insulin infusion as supplement to oral antidiabetic drugs in type 2 diabetes

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Tina Parkner
  • Torben Laursen
  • Jian-Wen Chen
  • ,
  • Marianne K Møller, Institut for Klinisk Medicin - Medicinsk Endokrinologisk Afd., MEA, NBG
  • ,
  • Henrik F. Thomsen
  • ,
  • Christina Jørgensen, Novo Nordisk A/S, Denmark
  • Jørgen S Smedegaard, Novo Nordisk A/S, Denmark
  • Torsten Lauritzen, Denmark
  • Jens S Christiansen, Denmark
  • The Department of Endocrinology and Diabetes
  • Department of Pharmacology
  • Department of Clinical Epidemiology
  • Institute of General Medical Practice
Basal continuous subcutaneous insulin infusion (CSII) therapy at a fixed rate may effectively improve glycemic control in patients with type 2 diabetes when oral antidiabetic treatment fails. Regimens of simple constant subcutaneous delivery of insulin may provide theoretical advantages in type 2 diabetes.
Original languageEnglish
JournalJournal of Diabetes Science and Technology
Pages (from-to)704-10
Number of pages7
Publication statusPublished - 1 Sep 2007

    Research areas

  • CSII, insulin analogue, insulin aspart, insulin pump, intermittent insulin pump, type 2 diabetes

See relations at Aarhus University Citationformats

ID: 34601577